Table 5.
Mutations by case status
| SNP* | CIN2+ n = 16 (%) |
Persistent n = 19 (%) |
Clearance/control n = 17 (%) |
|---|---|---|---|
| HPV16 | |||
| A51G | 0 | 0 | 1 (5.9) |
| T171C | 2 (12.5) | 3 (15.8) | 2 (11.8) |
| T228C | 3 (18.8) | 3 (15.8) | 2 (11.8) |
| T234G | 3 (18.8) | 3 (15.8) | 2 (11.8) |
| SNP | n = 13 (%) | n = 22 (%) | n = 12 (%) |
| HPV31 | |||
| G21A | 6 (46.2) | 9 (40.9) | 2 (16.7) |
| C67T | 1 (7.7) | 3 (13.6) | 4 (33.3) |
| C86T | 0 | 2 (9.1) | 0 |
| C111T | 3 (23.1) | 15 (68.2) | 6 (50.0) |
| G136A | 3 (23.1) | 14 (63.6) | 6 (50.0) |
| A184G | 13 (100.0) | 22 (100.0) | 12 (100.0) |
| G186C | 0 | 1 (4.5) | 2 (9.1) |
| SNP | n = 0 | n = 4 (%) | n = 14 (%) |
| HPV73 | |||
| A92G | – | 2 (50.0) | 10 (71.4) |
| C168T | – | 4 (100.0) | 13 (92.9) |
| G240T | – | 4 (100.0) | 13 (92.9) |
| A253G | – | 4 (100.0) | 12 (85.7) |
*
SNP single nucleotide polymorphism